The treatment of newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC) has evolved in recent years with the approval of hormonal agents such as Zytiga (Johnson & Johnson), Xtandi (Pfizer / Astellas Pharma), and the next-generation androgen receptor inhibitor Erleada (Johnson & Johnson). Although these therapies have improved patient outcomes, substantial unmet need remains for novel therapies with better efficacy and improved safety and tolerability. Therefore, the therapeutic management of newly diagnosed mHSPC presents an enormous commercial opportunity for drug developers.

QUESTIONS ANSWERED

  • What treatment drivers and goals are most likely to influence the choice of therapy for newly diagnosed mHSPC?
  • What attributes are key influencers of prescribing, and what are the hidden opportunities for drug developers?
  • What are the prevailing areas of unmet need and opportunity in this patient population?
  • What trade-offs across different clinical attributes and prices are acceptable to U.S. and European medical oncologists for a hypothetical therapy for newly diagnosed mHSPC?

PRODUCT DESCRIPTION

Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. One market scenario is profiled in detail by DRG experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulator.

Markets covered: United States, United Kingdom, France, Germany

Primary research: Survey of 61 U.S. medical oncologists and 30 European medical oncologists

Key drugs: Zytiga, Erleada, Xtandi, Taxotere / docetaxel generics

Table of contents

  • Prostate Cancer - Unmet Need - Detailed, Expanded Analysis - Metastatic Hormone Sensititve
    • Executive Summary
      • Unmet Need - Newly Diagnosed Metastatic Hormone-Sensitive Prostate Cancer - Executive Summary - September 2020
    • Introduction
      • Overview
      • Methodology
      • Rationale for Treatment Drivers and Goals Selection
        • Rationale for Drug Selection
          • Products for Newly Diagnosed Metastatic Hormone-Sensitive Prostate Cancer and Rationale for Drug Selection
      • Treatment Drivers and Goals
        • Key Findings: Attribute Importance
        • Relative Importance of Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Attributes to Surveyed Medical Oncologists' Prescribing Decisions in Newly Diagnosed Metastatic Hormone-Sensitive Prostate Cancer
        • Importance of Efficacy Attributes to Prescribing Decisions in Newly Diagnosed Metastatic Hormone-Sensitive Prostate Cancer: United States
        • Importance of Efficacy Attributes to Prescribing Decisions in Newly Diagnosed Metastatic Hormone-Sensitive Prostate Cancer: Europe
        • Importance of Safety and Tolerability Attributes to Prescribing Decisions in Newly Diagnosed Metastatic Hormone-Sensitive Prostate Cancer: United States
        • Importance of Safety and Tolerability Attributes to Prescribing Decisions in Newly Diagnosed Metastatic Hormone-Sensitive Prostate Cancer: Europe
        • Importance of Convenience of Administration Attributes to Prescribing Decisions in Newly Diagnosed Metastatic Hormone-Sensitive Prostate Cancer: United States
        • Importance of Convenience of Administration Attributes to Prescribing Decisions in Newly Diagnosed Metastatic Hormone-Sensitive Prostate Cancer: Europe
        • Key Findings: Stated vs. Derived Importance
        • Stated vs. Derived Importance of Key Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Attributes to Prescribing Decisions in Newly Diagnosed Metastatic Hormone-Sensitive Prostate Cancer: United States
        • Stated vs. Derived Importance of Key Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Attributes to Prescribing Decisions in Newly Diagnosed Metastatic Hormone-Sensitive Prostate Cancer: Europe
      • Product Performance Against Treatment Drivers and Goals
        • Key Findings
        • Overall Performance of Key Therapies for Newly Diagnosed Metastatic Hormone-Sensitive Prostate Cancer: United States
        • Overall Performance of Key Therapies for Newly Diagnosed Metastatic Hormone-Sensitive Prostate Cancer: Europe
        • Mean Overall Performance of Key Therapies for Newly Diagnosed Metastatic Hormone-Sensitive Prostate Cancer: United States and Europe
        • Relative Performance of Key Therapies for Newly Diagnosed Metastatic Hormone-Sensitive Prostate Cancer Across Select Efficacy Attributes: United States
        • Relative Performance of Key Therapies for Newly Diagnosed Metastatic Hormone-Sensitive Prostate Cancer Across Select Efficacy Attributes: Europe
        • Relative Performance of Key Therapies for Newly Diagnosed Metastatic Hormone-Sensitive Prostate Cancer Across Select Safety and Tolerability Attributes: United States
        • Relative Performance of Key Therapies for Newly Diagnosed Metastatic Hormone-Sensitive Prostate Cancer Across Select Safety and Tolerability Attributes: Europe
        • Relative Performance of Key Therapies for Newly Diagnosed Metastatic Hormone-Sensitive Prostate Cancer Across Convenience of Administration Attributes: United States
        • Relative Performance of Key Therapies for Newly Diagnosed Metastatic Hormone-Sensitive Prostate Cancer Across Convenience of Administration Attributes: Europe
      • Assessment of Unmet Need
        • Key Findings: Unmet Need in Newly Diagnosed Metastatic Hormone-Sensitive Prostate Cancer
        • Surveyed Medical Oncologists’ Satisfaction with the Performance of Key Therapies for Newly Diagnosed Metastatic Hormone-Sensitive Prostate Cancer on Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Factors: United States
        • Surveyed Medical Oncologists’ Satisfaction with the Performance of Key Therapies for Newly Diagnosed Metastatic Hormone-Sensitive Prostate Cancer on Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Factors: Europe
        • Surveyed Medical Oncologists' Ascribed Level of Unmet Need Across Key Efficacy Attributes in Newly Diagnosed Metastatic Hormone-Sensitive Prostate Cancer: United States
        • Surveyed Medical Oncologists' Ascribed Level of Unmet Need Across Key Efficacy Attributes in Newly Diagnosed Metastatic Hormone-Sensitive Prostate Cancer: Europe
        • Surveyed Medical Oncologists' Ascribed Level of Unmet Need Across Key Safety and Tolerability Attributes in Newly Diagnosed Metastatic Hormone-Sensitive Prostate Cancer: United States
        • Surveyed Medical Oncologists' Ascribed Level of Unmet Need Across Key Safety and Tolerability Attributes in Newly Diagnosed Metastatic Hormone-Sensitive Prostate Cancer: Europe
        • Surveyed Medical Oncologist' Ascribed Level of Unmet Need Across Key Convenience of Administration Attributes in Newly Diagnosed Metastatic Hormone-Sensitive Prostate Cancer: United States
        • Surveyed Medical Oncologists' Ascribed Level of Unmet Need Across Key Convenience of Administration Attributes in Newly Diagnosed Metastatic Hormone-Sensitive Prostate Cancer: Europe
        • Key Findings: Unmet Need in Newly Diagnosed Metastatic Hormone-Sensitive Prostate Cancer and Related Indications
        • Surveyed Medical Oncologists' Ascribed Level of Unmet Need in Newly Diagnosed Metastatic Hormone-Sensitive Prostate Cancer and Related Indications: United States
        • Surveyed Medical Oncologists' Ascribed Level of Unmet Need in Newly Diagnosed Metastatic Hormone-Sensitive Prostate Cancer and Related Indications: Europe
      • Opportunity Analysis
        • Areas of Opportunity in the Newly Diagnosed Metastatic Hormone-Sensitive Prostate Cancer Market and Emerging Therapy Insights
          • Opportunity: A New Therapy that can Prolong Overall Survival
          • Opportunity: A New Therapy that Delays Disease Progression and Skeletal-Related Events
          • Opportunity: A Novel Agent That Improves Prostate-Specific Antigen Response Rate
          • Opportunity: A Novel Therapy with Improved Safety and Tolerability
      • Target Product Profiles
        • Assessing Drug Development Opportunities
        • Target Product Profile Methodology
          • Attributes and Attribute Levels
          • Assigned Prohibitions for the Conjoint Module
        • Attribute Importance and Part-Worth Utilities
          • Newly Diagnosed Metastatic Hormone-Sensitive Prostate Cancer Target Product Profile: Attribute Importance
          • Median Overall Survival
          • Median Radiographic Progression-Free Survival
          • Time to Skeletal-Related Events
          • Incidence of Grade 3/4 Hypertension
          • Incidence of Any Grade Fatigue
          • Incidence of Any Grade Rash
          • Price per 28-Day Cycle
        • Conjoint Analysis-Based Simulation of a Market Scenario
          • Newly Diagnosed Metastatic Hormone-Sensitive Prostate Cancer Market Simulation: Share of Preference of Target Product Profiles Included in the Market Scenario
          • Newly Diagnosed Metastatic Hormone-Sensitive Prostate Cancer Market Simulation: Likelihood to Prescribe Target Product Profiles Included in the Market Scenario
          • Newly Diagnosed Metastatic Hormone-Sensitive Prostate Cancer Market Simulation: Target Product Profiles Included in the Market Scenario
      • Appendix
        • Key Abbreviations
        • Bibliography

    Author(s): Snigdha Gupta, Ph.D.

    Snigdha Gupta, Ph.D., is a principal analyst on the Oncology team at DRG, part of Clarivate. She has worked on multiple oncology indications, including non-small-cell lung cancer and multiple myeloma. She holds a Ph.D. in infectious diseases from the Indian Institute of Chemical Biology at Jadavpur University in Kolkata. She pursued a postdoctoral fellowship at the Mucosal Immunology Lab of the National Institute of Immunology in New Delhi and has been published in several peer-reviewed journals.


    Related Reports

    Prostate Cancer - Landscape & Forecast - Disease Landscape & Forecast

    Hormonal agents are the mainstay treatment for prostate cancer and are routinely used in all lines of therapy, even as novel agents like Orgovyx (Myovant) enter the treatment algorithm. Zytiga (Jan...

    View Details

    Prostate Cancer - Access & Reimbursement - Detailed, Expanded Analysis (US)

    The many premium-priced hormonal therapies for prostate cancer present a financial burden for payers. Moreover, costs are set to increase with the recent approvals of the LHRH antagonist Orgovyx fo...

    View Details

    Prostate Cancer | Disease Landscape and Forecast | G7 | 2020

    Prostate cancer is the most common cancer among men in developed countries. Hormonal agents are the mainstay of treatment for prostate cancer and are routinely used across lines. Zytiga (Johnson &a...

    View Details

    Prostate Cancer - Geographic Focus: China - Prostate Cancer - China In-Depth (China)

    Prostate cancer is the most common male urinary tumor and sixth most common male malignant tumor in China. Improved screening tools will result in a significant increase in the diagnosed incidence...

    View Details